Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04141462 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

EXOME Analysis Position in the Strategy of Genetic Predisposition Factors Identification in Early-onset Cancer

Study acronym: EX²TRICAN
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Apr 7, 2026 to Apr 7, 2028v4
  2. Primary completion date: Oct 7, 2026 to Apr 7, 2026 Completion date: Oct 7, 2026 to Apr 7, 2028 · Site contacts updated at 5 of 6 sitesv3 Show 2 more changesShow less
    • Completion date: Oct 7, 2026 to Apr 7, 2028
    • Site contacts updated at 5 of 6 sites
  3. Primary completion date: Oct 10, 2019 to Oct 7, 2026 Start date: Jul 2, 2019 to Oct 7, 2019 · Completion date: Oct 10, 2024 to Oct 7, 2026v2 Show 2 more changesShow less
    • Start date: Jul 2, 2019 to Oct 7, 2019
    • Completion date: Oct 10, 2024 to Oct 7, 2026
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
5 to 10% of cancers are due to the presence of a constitutional genetic alteration. It can be inherited from parents (family form) or by accident, in the first moments of life after fertilization (sporadic form). In both cases, this genetic alteration is constitutional and transmissible to descendants. It is hereditary. When an hereditary early form is suspected, several well-known genes generally involved in genetic predispositions to cancer are found by a technique called " gene panel ". However, this analysis does not always identify the genetic predisposing factors for cancer. New techniques called "high-throughput exome sequencing (SHD-E)", allow more than the analysis of the the gene panel. These analysis allow to identify alterations in other genes that could contribute to the development of cancer. The objective of the Ex²trican study is to show, from patients with early cancer (sporadic or familial form), that this approach to exome sequencing can be effective to identify new genetic risk of cancer, when the first panel analysis of genes is negative.
Trial Details
NCT Number NCT04141462
Lead Sponsor Centre Georges Francois Leclerc
Conditions Cancer, Genetic Predisposition
Enrollment 613 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov